Long Noncoding RNAs in Lung Cancer

2015 ◽  
pp. 57-110 ◽  
Author(s):  
Anna Roth ◽  
Sven Diederichs
Keyword(s):  
Lung Cancer ◽  
Noncoding Rnas ◽  
Long Noncoding Rnas

Biological functions of long noncoding RNAs and circular RNAs in small-cell lung cancer

Epigenomics ◽  
2020 ◽  
Vol 12 (19) ◽  
pp. 1751-1763
Author(s):  
Sachin Kumar ◽  
Monu Pandey ◽  
Surender K Sharawat
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Noncoding Rnas ◽  
Cancer Biomarkers ◽  
Small Cell ◽  
Long Noncoding Rnas ◽  
Circular Rnas ◽  
Small Cell Lung

We aim to discuss comprehensively the role of long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) in small-cell lung cancer (SCLC) biology and their clinical utility as cancer biomarkers. We searched the scientific literature to select articles related to the role of lncRNAs and circRNAs in SCLC biology or as cancer biomarkers. We identified that a number of lncRNAs and circRNAs can regulate key biological processes involved in SCLC development, including cell proliferation, metastasis and chemoresistance mainly acting as miRNA sponges. Also, the expression of a few lncRNAs and circRNAs predicted survival outcome depicting their utility as prognostic biomarkers. Further investigations on the role of lncRNAs and circRNAs in SCLC tumors may yield novel therapeutic targets for SCLC.

scholarly journals Analysis of Long Noncoding RNAs in Aila-Induced Non-Small Cell Lung Cancer Inhibition

2021 ◽  
Vol 11 ◽  
Author(s):  
Lin Chen ◽  
Cui Wu ◽  
Heming Wang ◽  
Sinuo Chen ◽  
Danhui Ma ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Noncoding Rnas ◽  
Small Cell ◽  
Long Noncoding Rnas ◽  
Dependent Manner ◽  
Small Cell Lung ◽  
Cancer Inhibition

Non-small cell lung cancer (NSCLC) has the highest morbidity and mortality among all carcinomas. However, it is difficult to diagnose in the early stage, and current therapeutic efficacy is not ideal. Although numerous studies have revealed that Ailanthone (Aila), a natural product, can inhibit multiple cancers by reducing cell proliferation and invasion and inducing apoptosis, the mechanism by which Aila represses NSCLC progression in a time-dependent manner remains unclear. In this study, we observed that most long noncoding RNAs (lncRNAs) were either notably up- or downregulated in NSCLC cells after treatment with Aila. Moreover, alterations in lncRNA expression induced by Aila were crucial for the initiation and metastasis of NSCLC. Furthermore, in our research, expression of DUXAP8 was significantly downregulated in NSCLC cells after treatment with Aila and regulated expression levels of EGR1. In conclusion, our findings demonstrate that Aila is a potent natural suppressor of NSCLC by modulating expression of DUXAP8 and EGR1.

scholarly journals The Emerging Roles of Long Noncoding RNAs as Hallmarks of Lung Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Jun Jiang ◽  
Yuan Lu ◽  
Fang Zhang ◽  
Jie Huang ◽  
Xin-ling Ren ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Drug Resistance ◽  
Prognostic Markers ◽  
Chromatin Modification ◽  
Noncoding Rnas ◽  
Cancer Biomarkers ◽  
Mechanisms Of Action ◽  
Long Noncoding Rnas ◽  
Ribonucleic Acids ◽  
New Class

Noncoding ribonucleic acids (ncRNAs) are closely associated with tumor initiation, growth, and progress in lung cancer. Long ncRNAs (lncRNAs), as one of the three subclasses of ncRNAs, play important roles in chromatin modification, transcription, and post-transcriptional processing. Various lncRNAs have recently been reported to be dysfunctional or dysregulated in cancers and have pro- or anti-tumor potential. Importantly, as a new class of cancer biomarkers, studies have demonstrated the plausibility of using certain subsets of lncRNAs as promising diagnostic, therapeutic, or prognostic strategies to manage cancers. This review focuses on lncRNAs associated with hallmarks of lung cancer, especially those discovered in the last five years. The expression levels of these lncRNAs in tumor samples are discussed, alongside their mechanisms of action, drug resistance, and potential as diagnostic and prognostic markers for lung cancer.

Differential long noncoding RNAs expression in cancer-associated fibroblasts of non-small-cell lung cancer

2019 ◽  
Vol 20 (3) ◽  
pp. 143-153 ◽  
Author(s):  
Cuifang Teng ◽  
Guolin Huang ◽  
Yanmei Luo ◽  
Yingxing Pan ◽  
Hanlin Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Noncoding Rnas ◽  
Small Cell ◽  
Long Noncoding Rnas ◽  
Cancer Associated Fibroblasts ◽  
Small Cell Lung

Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy

2016 ◽  
Vol 33 (2) ◽  
Author(s):  
Biagio Ricciuti ◽  
Clelia Mencaroni ◽  
Luca Paglialunga ◽  
Francesco Paciullo ◽  
Lucio Crinò ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Cancer Biology ◽  
Noncoding Rnas ◽  
Small Cell ◽  
Long Noncoding Rnas ◽  
Small Cell Lung ◽  
Diagnosis And Therapy

scholarly journals The Emerging Role and Promise of Long Noncoding RNAs in Lung Cancer Treatment

2016 ◽  
Vol 38 (6) ◽  
pp. 2194-2206 ◽  
Author(s):  
Ying Chen ◽  
Chen Li ◽  
Yan Pan ◽  
Siqi Han ◽  
Bing Feng ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Molecular Targeted Therapy ◽  
Recent Progress ◽  
Noncoding Rnas ◽  
Long Noncoding Rnas ◽  
Molecular Signaling ◽  
Protein Coding ◽  
Diagnostic Biomarkers ◽  
The World ◽  
Coding Capacity

Lung cancer is the leading cause of cancer death around the world. The advanced discovery of numerous long noncoding RNAs (lncRNAs) has dramatically changed the understanding of biology of human cancers, including lung cancer. LncRNAs are a group of noncoding RNAs (ncRNAs) with a length greater than 200 nucleotides with limited or no protein-coding capacity. Increasing evidence has shown that specific lncRNAs may be implicated in the process of tumorigenesis. Because of their roles in the regulation of multiple molecular pathways associated with changes in gene expression, lncRNAs can serve as potential diagnostic biomarkers or therapeutic targets in lung cancer. Importantly, dysregulated lncRNAs is reported to be correlated with the sensitivity of lung cancer cells to anticancer therapies, including chemotherapy, molecular-targeted therapy, etc. Herein, we review the recent progress of lncRNAs in lung cancer, with a particular focus on the multiple molecular roles of regulatory lncRNAs on the molecular signaling pathways involved in tumorigenesis and the resistance to such therapies.

Sign in / Sign up

Export Citation Format

Share Document